ReviewGastroenterology2009
Helicobacter pylori in health and disease.
Review in Gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05374980 (The Effects of Fermented Milk Product With Probiotic on Helicobacter Pylori Infection, Gut Microbiome and Metabolism.), which is not on this map. Cited by 352 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Fermented Milk Product With Probiotic on Helicobacter Pylori Infection, Gut Microbiome and Metabolism.
Who cites it
352 citing papers in PubMed, 3 syntheses or guidelines pooled it, 698 citations in OpenAlex.
- Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2019Pooled it
- Changing trends in the prevalence of H. pylori infection in Japan (1908-2003): a systematic review and meta-regression analysis of 170,752 individuals.Scientific reports · 2017Pooled it
- Periodontal therapy as adjunctive treatment for gastric Helicobacter pylori infection.The Cochrane database of systematic reviews · 2016Pooled it
- Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial.BMC gastroenterology · 2025Trial
- Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2017Trial
- First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.World journal of gastroenterology · 2015Trial
- Review
- Development of Fluorogenic Probes to Detect Glycan-Degrading Enzymes in Bacteria.ACS infectious diseases · 2026Article
- Multiple TonB-dependent transport systems inInfection and immunity · 2026Article
- Contributions of conserved and species-specific CagX (VirB9) domains to the assembly and function of theInfection and immunity · 2026Article
- Methylation Dynamics inMicroorganisms · 2026Article
- Community-BasedPublic health reports (Washington, D.C. : 1974) · 2026Article
- Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential.Genes & diseases · 2026Review
- Review
- Crystal structure of carbon-nitrogen hydrolase from Helicobacter pylori G27.Acta crystallographica. Section F, Structural biology communications · 2026Article
- Species-level dynamics of gastric microbiome after Helicobacter pylori eradication in high-risk Mongolian population.Gut pathogens · 2026Article
- Determination of Potential Inhibitors againstCurrent pharmaceutical design · 2026Review
- Endoscopic predictors of iron deficiency in Helicobacter pylori gastritis: a Kyoto classification-based study.Clinical endoscopy · 2026Article
- On the Role of Food in the Transmission ofFoods (Basel, Switzerland) · 2025Review
- The multi-kingdom cancer microbiome.Nature microbiology · 2025Review
292 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Helicobacter pylori is highly adapted for colonization of the human stomach and is present in about half of the human population. When present, H pylori is usually the numerically dominant gastric microorganism. H pylori typically does not cause any adverse effects, but it is associated with an increased risk of noncardia gastric adenocarcinoma, gastric lymphoma, and peptic ulcer. Disorders such as esophageal diseases and childhood-onset asthma were recently reported to occur more frequently in individuals who lack H pylori than in H pylori-positive persons. In this review, we discuss biologic factors that allow H pylori to colonize the human stomach, mechanisms by which H pylori increases the risk of peptic ulcer disease and noncardia gastric adenocarcinoma, and potential benefits that H pylori might confer to humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.